Skip to main content
Premium Trial:

Request an Annual Quote

That's Not Supposed to Happen


Cancer cells are hard to get rid of because they continually find ways to evade treatment and survive. That's what a new study in Cancer Cell makes clear, says Tim Barribeau at the IO9 blog. The researchers studied anti-angiogenic therapies, which shrink tumors by going after pericytes — the cells that help tumors make blood vessels to feed themselves. They found that while tumors in pericyte-knockdown mice with actually shrank, that result was accompanied by "a threefold increase in the formation of secondary tumors," Barribeau says. "By cutting back on their size, the tumors metastasized far more readily."

So even though the treatment seemed to control the tumor's growth, says the study's senior author Raghu Kalluri, it actually enabled the cancer to spread. "When the blood supply is reduced to the cancer, it goes into survival mode, transitioning to having more mobile cells," Barribeau adds. "Without the pericytes, the blood vessels around the tumor become leaky, which the cancer cells are able to infiltrate far more readily, and spread to other region." When the researchers analyzed human breast cancer tumor samples, they found that, as in the mice, low pericyte levels were associated with metastasis and low survival rates.

But it's not all bad news, Barribeau says. The study shows that such metastases are also associated with an increased expression of Met, which is associated with cell migration and growth. Using Met-inhibitors could help prevent such metastases, Barribeau adds.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more